Abstract
Background
Practice guidelines have been developed for early-stage and locally advanced non-small cell lung cancer (NSCLC). However, many common clinical scenarios still require individualized decision making. This is true for locoregional relapse after initial stereotactic radiotherapy (stereotactic body radiation therapy or stereotactic ablative radiotherapy; SBRT or SABR), an increasingly utilized curative treatment option for stage I NSCLC.
Methods
A consortium of expert radiation oncologists was established with the aim of providing treatment recommendations. In this scenario, a case was distributed to six radiation oncologists who provided their institutions’ treatment recommendations. In this case, a patient developed local and mediastinal relapse after SABR (45 Gy, 3 fractions), comparable to the tumor burden in de novo stage IIIA NSCLC. Treatment recommendations were tabulated and a consensus conclusion was developed.
Results
Three institutions recommended evaluation for surgery. If the patient was not a surgical candidate, and/or refused surgery, definitive chemoradiation was recommended, including retreating the primary to full dose. European participants were more in favor of a non-surgical approach. None of the participants were reluctant to prescribe reirradiation, but two institutions prescribed doses lower than 60 Gy. Platinum-based doublets together with intensity-modulated radiotherapy were preferred.
Conclusion
The institutional recommendations reflect the questions and uncertainties discussed in current stage III guidelines. All institutions agreed that previous SABR is not a contraindication for salvage chemoradiation. In the absence of high-quality prospective trials for recurrent NSCLC, all treatment options recommended in current guidelines for stage III disease can be considered in clinical scenarios such as this.
Zusammenfassung
Hintergrund
Für frühe und lokal fortgeschrittene Stadien des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) wurden Behandlungsleitlinien publiziert. Dennoch erfordern einige klinische Situationen individuelle Entscheidungen. Dazu gehört ein lokoregionales Rezidiv nach stereotaktischer Strahlentherapie (SABR), einer Modalität, die immer öfter im Stadium I angewandt wird.
Methoden
Eine Expertengruppe wurde etabliert, um Empfehlungen zur Rezidivbehandlung zu erarbeiten. Insgesamt 6 Radioonkologen brachten die Behandlungsempfehlungen ihrer Institution ein. In dem Fall entwickelte ein Patient ein Lokal- und Mediastinalrezidiv nach SABR (45 Gy, 3 Fraktionen), vergleichbar mit der Ausbreitung beim De-novo-NSCLC im Stadium IIIA. Empfehlungen wurden in Tabellen verglichen und ein Konsensus wurde ausgearbeitet.
Ergebnisse
Drei Institutionen empfahlen eine chirurgische Konsultation. Kam eine Operation nicht infrage oder wurde vom Patienten abgelehnt, empfahlen sie eine definitive Radiochemotherapie, einschließlich einer erneuten Behandlung des Primärtumors mit der vollen Dosis. Europäische Teilnehmer bevorzugten eine konservative Therapie. Keiner der Teilnehmer war zurückhaltend, eine Rebestrahlung zu verschreiben, aber zwei Institutionen wählten Gesamtdosen <60 Gy. Platinbasierte Kombinationen mit intensitätsmodulierter Strahlentherapie wurden bevorzugt.
Schlussfolgerung
Die Empfehlungen der beteiligten Zentren reflektieren die Kontroversen und Unsicherheiten der aktuellen Leitlinien für das Stadium III. Alle Institutionen waren einig, dass eine initiale SABR keine Kontraindikation für eine Salvage-Radiochemotherapie darstellt. Solange keine prospektiven Daten für rezidivierte NSCLC vorliegen, können in klinischen Szenarien, wie dem hier geschilderten, alle Behandlungsoptionen der Leitlinien für das Stadium III erwogen werden.
Similar content being viewed by others
References
Kong FM, Cuneo KC, Wang L et al (2014) Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology. Pract Radiat Oncol 4:e133–141
Schanne DH, Nestle U, Allgäuer M et al (2015) Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191:125–132
Kelley KD, Benninghoff DL, Stein JS et al (2015) Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy. Radiat Oncol 10:120
Nieder C, Andratschke NH, Guckenberger M (2015) A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question? Ann Transl Med 3:148
Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637
Shaverdian N, Wang PC, Steinberg M, Lee P (2015) The patient’s perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC). Lung Cancer 90:230–233
Farjah F, Lou F, Sima C, Rusch VW, Rizk NP (2013) A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography. J Thorac Oncol 8:1170–1180
Cuaron J, Dunphy M, Rimner A (2013) Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol 2:208
Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 101:1623–1631
Onishi H, Shirato H, Nagata Y et al (2011) Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81:1352–1358
Mehta N, King CR, Agazaryan N et al (2012) Stereotactic body radiation therapy and 3‑dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol 2:288–295
Mokhles S, Verstegen N, Maat AP et al (2015) Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer 87:283–289
VanderMeer R, Chambers S, Van Dam A, Cutz JC, Goffin JR, Ellis PM (2015) Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care? Curr Oncol 22:272–278
Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM (2015) Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: Safety and efficacy. Int J Radiat Oncol Biol Phys 92:325–331
Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S (2012) Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 13:802–809
Spratt DE, Wu AJ, Adeseye V et al (2016) Recurrence patterns and second primary lung cancers after stereotactic body radiotherapy for early-stage non-small cell lung cancer: implications for surveillance. Clin Lung Cancer 17:177–183
Van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J (2015) Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol 10:826–831
Ward MC, Oh SC, Pham YD et al (2016) Isolated nodal failure after stereotactic body radiotherapy for lung cancer: the role for salvage mediastinal radiotherapy. J Thorac Oncol 11:1558–1564
Verstegen NE, Lagerwaard FJ, Hashemi SM, Dahele M, Slotman BJ, Senan S (2015) Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer: optimizing follow-up schedules for salvage therapy. J Thorac Oncol 10:1195–1200
Hamaji M, Chen F, Matsuo Y, Ueki N, Hiraoka M, Date H (2015) Treatment and prognosis of isolated local relapse after stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: importance of salvage surgery. J Thorac Oncol 10:1616–1624
Oberije C, De Ruysscher D, Houben R et al (2015) A validated prediction model for overall survival from stage III non-small cell lung cancer: toward survival prediction for individual patients. Int J Radiat Oncol Biol Phys 92:935–944
Eberhardt WE, De Ruysscher D, Weder W et al (2015) 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 26:1573–1588
Chang JY, Kestin LL, Barriger RB et al (2014) ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology 28:706–710
Ramnath N, Dilling TJ, Harris LJ et al (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e314S–340S
Willers H, Stinchcombe TE, Barriger RB et al (2015) ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. Am J Clin Oncol 38:197–205
Rodrigues G, Choy H, Bradley J et al (2015) Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 5:141–148
Bezjak A, Temin S, Franklin G et al (2015) Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol 33:2100–2105
Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199
Jalal SI, Riggs HD, Melnyk A et al (2012) Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 23:1730–1738
De Ruysscher D, Faivre-Finn C, Le Pechoux C, Peeters S, Belderbos J (2014) High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. Lancet Oncol 15:e620–e624
Kruser TJ, McCabe BP, Mehta MP et al (2014) Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol 37:70–76
Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD (2014) Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol 9:210
Patel NR, Lanciano R, Sura K et al (2015) Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses. J Radiat Oncol 4:65–70
Evans JD, Gomez DR, Amini A et al (2013) Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol 106:327–332
Peulen H, Karlsson K, Lindberg K et al (2011) Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 101:260–266
Kilburn JM, Kuremsky JG, Blackstock AW et al (2014) Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 110:505–510
Meng MB, Wang HH, Zaorsky NG et al (2015) Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget 6:15690–15703
Kilburn JM, Lester SC, Lucas JT Jr et al (2014) Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol 9:572–576
Oskan F, Becker G, Bleif M (2017) Specific toxicity after stereotactic body radiation therapy to the central chest: a comprehensive review. Strahlenther Onkol 193:173–184
Binkley MS, Hiniker SM, Chaudhuri A et al (2016) Dosimetric factors and toxicity in highly conformal thoracic reirradiation. Int J Radiat Oncol Biol Phys 94:808–815
Sumita K, Harada H, Asakura H et al (2016) Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study. Radiat Oncol 11:104
Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U (2013) Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomized trial by the Norwegian Lung Cancer Study Group. Br J Cancer 109:1467–1475
Machtay M, Paulus R, Moughan J et al (2012) Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 7:716–722
Rajpara RS, Schreibmann E, Fox T et al (2014) Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer. Radiat Oncol 9:187
De Ruysscher D, Faivre-Finn C, Nestle U et al (2010) European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 28:5301–5310
Nieder C, Pawinski A, Andratschke NH (2013) Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations. Front Oncol 3:176
Fleckenstein J, Eschler A, Kremp K, Kremp S, Rübe C (2015) Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis. Radiat Oncol 10:178
Flentje M, Huber RM, Engel-Riedel W et al (2016) GILT – a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192:216–222
Lee SU, Moon SH, Cho KH et al (2016) Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas: Ablative dose PBT for NSCLC. Strahlenther Onkol 192:649–657
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
C. Nieder, D. De Ruysscher, L.E. Gaspar, M. Guckenberger, M.P. Mehta, P. Cheung, and A. Sahgal declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Nieder, C., De Ruysscher, D., Gaspar, L.E. et al. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease. Strahlenther Onkol 193, 515–524 (2017). https://doi.org/10.1007/s00066-017-1130-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-017-1130-0